Adela

We are uncompromising in our adherence to strong ethical principles and values. Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease.‍Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Lisa is a mission-driven entrepreneur dedicated to improving patient care and advancing the adoption of precision medicine. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a genetic information company, and was part of the start-up team at Genomic Health Inc. Scott Bratman is a physician-scientist known for developing novel liquid biopsy methods with immense clinical impact. Daniel De Carvalho is the scientific co-founder at Adela. Daniel is a world-leader in cancer epigenomics research and since 2012 has led a research group at the Princess Margaret Cancer Centre and the University of Toronto. Karla is a Director of The Forsyth Institute and the Leadership Board of Beth Israel Deaconess Medical Center.